Regarding ORR, Patients with ESCC receiving PD-1 inhibitors (OR = 2.07, 95% CI: 1.22-3.52) were more likely to experience an improvement in ORR compared to those receiving standard chemotherapy. Here, PDCD1 is linked to esophageal squamous cell carcinoma.